Navigation Links
Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
Date:2/11/2013

CASTLE ROCK, Colo., Feb. 11, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that its presentation at the 2013 BIO CEO and Investor Conference, to be held February 11-12, 2013, at the Waldorf Astoria Hotel in New York, has been rescheduled for Tuesday, February 12, 2013. 

Steve Lundy , President and CEO of Venaxis, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:BIO CEO and Investor ConferenceDate: Tuesday, February 12, 2013 Time: 10:00 am (Eastern Time) Location:Astor Room, 3rd Floor; Waldorf Astoria Hotel; New YorkThe presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com.  The webcast replay will remain available for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm , PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis to Present at 2013 BIO CEO and Investor Conference
2. AspenBio Pharma Changes Company Name to Venaxis, Inc.
3. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
4. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
8. Wacoms DTH-2242: An Ideal Interactive Pen and Touch Display Solution for Healthcare and Presentation Markets
9. Présentation du tout premier test pratique dévaluation des compétences pour la certification dendoscopie
10. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
11. Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
(Date:3/23/2017)... Care, based in St. Joseph, Missouri , has selected AccuReg to ... located in 22 cities, and its flagship St. Joseph Medical Center. Mosaic ... health care to its patients, including the insurance, billing and collections processes. ... ... Care St. Joseph Medical Center ...
(Date:3/23/2017)... and INDIANAPOLIS , March ... LLY ) and the William Sansum Diabetes Center ... of Latino people affected by diabetes through enhanced research, ... of diabetes and cardiovascular disease bears a disproportionate weight ... ," said David Kerr , M.D., FRCPE, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the opening ... at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the new ... in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an even ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... Texas ... located at 960 Gruene Road in Building 2. The clinic is the group’s second ... Bennett, PT, says opening the company’s second New Braunfels location brings things full circle ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... and individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT to ...
Breaking Medicine News(10 mins):